Invasive pneumococcal disease among children in Victoria by Liu, Min et al.
Invasive pneumococcal disease among
children in Victoria
Min Liu,
1,2
Ross Andrews,
2,3
Joanne Stylianopoulos,
4
Catherine Ferreira,
2
Geoff Hogg,
4
Nyree Pyper
2
Abstract
This study analysed notification data from the first year of enhanced surveillance of invasive pneumococcal
disease (IPD) in Victoria (1 July 2001 – 30 June 2002), with a focus on risk factors for infection and
vaccination status among children under five years of age. Overall, there were 397 notifications (8.2 per
100,000 population), 131 (33%) were children under five years of age. The highest notification rates were
among those aged less than two years (72.6 per 100,000 population). Among children aged less than five
years: bacteraemia without a primary focus of infection was the most common clinical presentation
(64%); 89 per cent were hospitalised with the median length of stay being three days; four children (3%)
died. There were 107 cases of a known serotype, 92% (n=98) were either in or closely related to those
included in the 7-valent conjugate pneumococcal vaccine (7vPCV). Most cases (98%) were not eligible
for free 7vPCV under the currently funded program in Victoria. Only one child had been vaccinated.
The results from the first year of enhanced IPD surveillance in Victoria suggest consideration should be
given to extending the publicly funded program to include all children under two years of age. Commun
Dis Intell 2003;27:362–366.
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Introduction
Streptococcus pneumoniae causes morbidity and
mortality in both developing and developed countries,
predominantly among young children and the aged.1
Invasive pneumococcal disease (IPD), that is where
S. pneumoniae is isolated from a normally sterile
site, usually presents as pneumonia, meningitis or
bacteraemia (without a primary focus of infection).
S. pneumoniae has gradually become more resistant
to penicillin and other antibiotics.2
Victoria is participating in a national program of
enhanced IPD surveillance under the auspices of the
Communicable Diseases Network Australia
(CDNA).3 Since May 2001, all medical practitioners
and laboratories in Victoria have been required to
notify the Department of Human Services (DHS) of
all IPD diagnoses pursuant to the Health (Infectious
Diseases) Regulations 2001.
A 7vPCV (PrevenarTM, Wyeth-Lederle Vaccines) has
been licensed and approved for use among children
six weeks to nine years of age in Australia,4 but
public funding for the vaccine in Victoria is only
available to Indigenous children under two years of
age or children under five years of age with one of the
following medical risk factors:5
• impaired immunity;
– congenital immune deficiency including
symptomatic IgG subclass or isolated IgA
deficiency;
– disease associated with immunosuppressive
therapy or radiation therapy;
– compromised splenic function due to sickle
haemoglobinopathies or congenital or acquired
asplenia;
– HIV infection;
– renal failure or relapsing or persistent nephrotic
syndrome;
• anatomical abnormalities;
– cardiac disease associated with cyanosis or
cardiac failure;
– proven or presumptive cerebrospinal fluid leak.
This article describes the epidemiology of IPD in
Victoria based on the first 12 months of notification
data, with a focus on risk factors for infection and
vaccination status of children under five years of age.
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Methods
A case of IPD was defined as a clinical condition
where S. pneumoniae was isolated from blood,
cerebrospinal fluid or other normally sterile site or
detected by nucleic acid testing, e.g. polymerase
chain reaction, in a normally sterile site.
All notifications of IPD received by DHS from 1 July
2001 to 30 June 2002 were included. The treating
practitioner of each notified case was contacted by
telephone or facsimile to confirm clinical details, risk
factors for infection and vaccination status as a
component of a national program of enhanced IPD
surveillance.3 The primary diagnostic laboratory was
encouraged to forward cultures from normally sterile
sites to the Microbiological Diagnostic Unit, Public
Health Laboratory, Melbourne University, for
serotyping.
Risk factor data for notifications related to children
under five years of age included: immunocompromising
conditions (e.g. HIV/AIDS, organ transplant, multiple
myeloma, asplenia, chronic drug therapy); chronic
illness (e.g. chronic respiratory, heart, liver or renal
disease, diabetes); prematurity (<37 weeks gestation);
low birth weight (<2,500 g); congenital or chromosomal
abnormality; cigarette smoker in the household.
More than one risk factor could be reported. Cases
were classified according to the identified risk factors
as: immunocompromised; any other identified risk
factor; no identified risk factor; or as unspecified (if no
records were available). Immunocompromised cases
who also had other risk factors were classified as
immunocompromised.
For all children under five years of age, vaccination
status was checked against the Australian Childhood
Immunisation Register (ACIR). In order to be
considered vaccinated or partially vaccinated, a
pneumococcal vaccine must have been given at
least two weeks prior to illness onset. The Australian
Bureau of Statistics Estimated Residential Population
for Victoria, as at 30 June 2001, was used as the
source for denominator data when calculating
notification rates.
Results
All ages
From 1 July 2001 to 30 June 2002, DHS received
397 notifications of IPD, ranging from 18 cases in
February 2002 to a peak of 56 cases in August 2001.
There were 213 notifications for males (56%) and
184 females (44%). The notification rate was 8.2 cases
per 100,000 population. Thirty-three per cent of the
notifications (n=131) were for children under five
years of age. Age-specific rate notification rates were
highest among those aged less than five years (42.1 per
100,000 population) and those aged 85 years or
more (35.6 per 100,000 population) (Figure). For the
younger age group, rates were highest among
children aged less than two years (72.6 per 100,000
population). There were 22 deaths due to IPD (6%),
the highest case fatality rate was among those aged
65 years or more (10%, 12 deaths).
Four notifications (1%) were Aboriginal persons (aged
from 39–46 years), 325 (82%) were not Aboriginal or
Torres Strait Islander persons whilst Indigenous status
was not specified for the remaining 68 cases (17%).
Children under five years of age
Of the 131 notifications among children aged less
than five years, 84 (64%) had bacteraemia without a
primary focus of infection, 27 (21%) presented with
pneumonia and 13 (10%) with meningitis (one child
presented with pneumonia and meningitis). The foci
of infection were not specified for the remaining eight
cases (6%). One hundred and seventeen cases were
hospitalised (89%), seven (5%) were not hospitalised
whilst hospitalisation status was not established for
the remaining seven (5%). The median length of stay
for hospitalised cases was three days (range
0–86 days) and the interquartile range was 2–3 days.
Four deaths were reported among children aged less
than five years (3% case fatality rate). A 17-month-old
child with serotype 18C had bacteraemia without
primary focus. The second fatality was an infant
aged two months who had serotype 19A identified
from a post mortem lung culture. The cause of death
was confirmed as bilateral broncho-pneumonia by
the Coroner and the Chief Pathologist. The third
fatality was a two-year-old child who presented with
meningitis and had serotype 19F identified from
cerebrospinal fluid. The fourth fatality was a
15-month-old child with a positive blood culture and
clinical meningitis features for whom the serotype
was unknown. Of the three deaths due to known
serotypes, two were a type contained in the 7vPCV.
No risk factor information was obtained for the child
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Figure. Age-specific notification rate of
invasive pneumococcal disease,
Victoria, 1 July 2001 to 30 June 2002
diagnosed post mortem, while none of the other
children were immunocompromised or identified as
having any other risk factor.
Serotypes
Serotypes were identified for 107 cases (82%), one
isolate was unable to be typed (1%) and cultures
were not forwarded for serotyping for the remaining
23 cases (18%). Of the 107 with a known serotype,
95 (89%) were serotypes contained in the 7vPCV,
while another 3 (3%) were serotype 6A for which the
vaccine is likely to confer protection since it is closely
related to a serotype contained within the 7vPCV.6
Eight of the nine remaining cases were caused by
serotypes contained in the 23 valent polysaccharide
pneumococcal vaccine (7F, 11A, 15B and 19A) but
only one of these was old enough (>2 years) to have
received that vaccine (Table 1).7
Vaccination status and risk factors
One child, who had biliary atresia and was awaiting a
liver transplant, had recurrent bacteraemia within the
study period (both episodes were serotype 14). The
first episode occurred at 10 months of age, the child
received a first dose of 7vPCV five days prior to
illness onset so was not expected to have developed
an immune response within that time. The second
episode occurred at age 11.5 months and by that
time, the child had received two doses at least two
weeks prior to illness onset (the second dose of
7vPCV was given 12 days after the first).
Three cases (2%) were in a risk group eligible for the
free vaccine in Victoria, all were immunocompromised.
One of these was infected with a serotype not
contained in the 7vPCV—the child, aged four months,
had received a bone marrow transplant and had
serotype 11A isolated from a blood culture. The other
two children were both infected with serotypes
contained in the 7vPCV (14 and 18C)—one child, aged
three years, was receiving treatment for leukaemia
while the other child, aged four years, had acute
lymphatic lymphoma. All three children had
bacteraemia without a primary focus of infection.
Twenty-six children (20%) had a risk factor for IPD
other than those for which the vaccine is currently
funded, 89 (68%) had no identified risk factor, and
there was insufficient information available to enable
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Table 1. Vaccine and non-vaccine serotypes of invasive pneumococcal disease identified among
children aged less than 5 years, Victoria, 1 July 2001 to 30 June 2002
Vaccine Serotype Age (years) Total Cumulative
<1 1 2 3 4 n % %
7vPCV 14 12 13 7 3 4 39 36 36
6B 7 9 1 1 18 17 53
18C 2 5 3 2 1 13 12 65
19F 5 3 2 10 9 75
4 3 1 2 1 7 7 81
23F 3 1 1 5 5 86
9V 1 2 3 3 89
Related* 6A 1 1 1 3 3 92
Subtotal 26 36 17 9 10 98 92 92
23vPPV 19A 2 3 5 5 96
11A 1 1 1 97
15B 1 1 1 98
7F 1 1 1 99
Neither 18B 1 1 1 100
Total 30 40 17 9 11 107 100 100
Others 12 8 0 3 2 25 N/A
7vPCV refers to serotypes contained in the 7 valent conjugate pneumococcal vaccine.
* Serotype 6A is not contained in the 7vPCV but is closely related to Serotype 6B.
23vPPV refers to serotypes contained in the 23 valent polysaccharide pneumococcal vaccine but not in the 7vPCV.
Other includes one isolate for a child aged <1 year that was not typable and 24 isolates that were not forwarded for serotyping.
N/A Not applicable with respect to proportions of vaccine and non-vaccine serotypes.
identification of any risk factors for the remaining
12 children (9%) (Table 2). Information on smoking in
the household was poorly reported with 67 per cent
(n=88) recorded as unknown or not stated, even so
this was the most prevalent risk factor reported
(10 children, 8% of 130). It is likely that more cases
with this risk factor would have been identified if
interviews had also been conducted with the
parent/guardian. Chronic illness and gestation
related risk factors were more completely reported
with the proportions unknown or not stated ranging
from 30–34 per cent. The congenital or chromosomal
abnormalities identified were: Arnold-Chiari
syndrome; anomalous pulmonary venous drainage;
biliary atresia; cardiac murmur/pulmonary stenosis;
Down’s syndrome; Hirschsprung’s disease; infantile
osteopetrosis and translocation of chromosome 3&6.
Discussion
IPD first became notifiable in Victoria on 15 May
2001. This is the first report including a full 12 months
data since that time and includes the information
collected through enhanced surveillance in Victoria.
This report has focussed on children less than five
years of age because this is a group with high rates
of disease and includes a subgroup for which the
7vPCV is publicly funded.5
Other jurisdictions, such as metropolitan New South
Wales and the United States of America have reported
rates approaching, or in excess of, 100 cases per
100,000 children under two years of age.8,9 In
Victoria, the notification rate for children aged less
than five years (42.1 cases per 100,000 population)
was slightly lower than the national rate reported
recently (47.3 cases per 100,000 population).3 For
children less than two years of age, the notification
rate (72.6 cases per 100,000 population) represented
a 23 per cent increase on data collated prior to IPD
becoming a notifiable condition in Victoria.10 However,
it is likely that the true disease burden remains
under-reported. Failure to test or failure to test prior
to commencement of antibiotics are factors that have
been identified as contributing to under-reporting.11
Failure to notify all diagnosed cases to DHS could
also be a factor given that this was the first year the
condition was notifiable.
Even though the notification rate was highest in
children under two years of age and serotyping
showed that 92 per cent of cases in this age group
were of a type included in/or closely related to those
in the 7vPCV, only one child had been vaccinated. Of
all the cases detected in children under five years of
age, only three (2%) were eligible for free vaccine
under the current program.
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Table 2. Risk factors of invasive pneumococcal disease identified among children aged less than 5
years, Victoria, 1 July 2001 to 30 June 2002
Risk factor Age (years) Total*
<1 1 2 3 4 n %
Immunocompromised 1 0 0 1 1 3 2
Any other identified risk factor (see below) 10 7 2 5 2 26 20
No identified risk factor 25 37 14 6 7 89 68
Unspecified 4 4 1 0 3 12 9
Total 40 48 17 12 13 130 100
Any other identified risk factor including: 10 7 2 5 2 26 20
Chronic illness 2 3 1 2 1 9 7
Premature birth 2 2 2 0 1 7 5
Low birth weight 1 1 2 1 0 5 4
Congenital or chromosomal abnormality 5 2 1 0 0 8 6
Smoker in household 5 2 0 2 1 10 8
* Total refers to children (n=130) not notifications (one child had two episodes during study period)
† More than one risk factor could be identified for each notified case
The 7vPCV is currently funded for those groups in
Australia at highest risk of pneumococcal disease:
Indigenous children to the age of two years and
non-Indigenous children to the age of five years in
specified risk groups.4 Our data showed that, within
Victoria, the disease burden was predominantly among
children outside the funded risk groups (98%). Whilst
it is acknowledged that risk factor information collated
through the enhanced surveillance may be incomplete,
it is not believed that the information collected from
treating practitioners is likely to substantially
under-estimate the proportion of children eligible for
the 7vPCV under the currently funded program.
The 7vPCV contains serotypes that most frequently
cause invasive antibiotic-resistant disease.12 Both
the efficacy and cost-effectiveness of the vaccine
have shown that it has the potential to have a
significant public health impact on the incidence of
IPD.13,14 Assuming 92 per cent of all cases in children
were caused by serotypes contained in the 7vPCV,
then, given vaccine efficacy of 94 per cent, we could
expect that a universal vaccination program in Victoria
could prevent 86 per cent of invasive pneumococcal
disease in children old enough to complete the primary
course.
In the United States of America, conjugate
pneumococcal vaccine has been recommended for
all children under two years of age.15 A recent report
on invasive pneumococcal disease in north
Queensland, an area with a much higher proportion
of Indigenous children than Victoria, suggested that
there may be a case for extending the publicly
funded 7vPCV program to include all non-indigenous
children under two years of age.16 The results from
the first year of enhanced surveillance in Victoria
support this view.
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